What is the recommended dose of octreotide (somatostatin analogue) for managing high ileostomy output?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Octreotide Dosage for High Ileostomy Output

The recommended dose of octreotide for managing high ileostomy output is 50 micrograms subcutaneously twice daily. 1

Dosing Considerations

  • Octreotide should be administered subcutaneously, with the standard initial dose being 50 micrograms twice daily 1
  • The medication should be given before meals as intestinal output, especially in net "secretors," rises after meals 1
  • Octreotide is most effective in patients with net secretory output (generally more than 3 L/24 hours) and can reduce stomal output by 1-2 L/24 hours 1, 2
  • For patients with extremely high output, dosing may need to be increased to 100 micrograms three times daily, though this should be done under careful monitoring 3, 2

Mechanism and Effectiveness

  • Octreotide is a somatostatin analogue that decreases gastric, biliary, and pancreatic secretions 1
  • It inhibits secretagogue-induced water and electrolyte secretion in the jejunum, stimulates sodium and chloride absorption in the ileum, decreases intestinal motility, and inhibits the release of hormones that may contribute to diarrhea 1
  • Studies show octreotide can reduce ileostomy diarrhea and large volume jejunostomy output, with the greatest reductions seen in those with net secretory output 1, 2
  • The effect of octreotide is maintained in the long term 1

Monitoring and Precautions

  • Careful monitoring is essential when initiating octreotide therapy to prevent fluid retention, which can occur especially in patients with the highest stomal outputs 1
  • A mean reduction of approximately 50% of fistula/stoma output is typically noted within 24 hours of octreotide administration 4
  • Objective measurements of the effects should be performed before and during treatment 1
  • Parenteral support should be reduced accordingly as stomal output decreases 1
  • Long-term use requires monitoring for potential adverse effects and possible negative interference with the process of intestinal adaptation 1

Alternative and Adjunctive Therapies

  • Octreotide should be considered after first-line interventions have failed, including:
    • Restricting oral hypotonic fluids to 500 ml/day 1
    • Using glucose-saline solution with sodium concentration of at least 90 mmol/L 1
    • Administering antimotility drugs such as loperamide (2-8 mg before food) 1
  • Drugs that reduce gastric acid secretion (H2 antagonists or proton pump inhibitors) are as effective as octreotide in reducing stomal output volume and should be considered as alternatives 1
  • For patients who fail to respond to conventional treatments including octreotide, newer GLP-2 analogues like teduglutide may be considered, though these should only be prescribed by specialists 1

Common Pitfalls and Caveats

  • Octreotide should be used especially in the short-term after intestinal resection when fluid and electrolyte management is problematic despite conventional treatments 1
  • While octreotide reduces stomal output, it does not change the absorption of energy, carbohydrate, lipid, or nitrogen, and may not reduce jejunostomy output enough to eliminate the need for parenteral fluid and electrolyte replacement 1
  • Long-acting octreotide/somatostatin preparations have not been well assessed in large studies for this indication 1
  • Potential adverse effects include pain or burning at the injection site, abdominal pain, and diarrhea 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Short bowel syndrome.

Digestion, 1990

Research

Octreotide, a new somatostatin analogue.

Clinical pharmacy, 1989

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.